Computational design of newly engineered DARPins as HER2 receptor inhibitors for breast cancer treatment

Computational design of newly engineered DARPins as HER2 receptor inhibitors for breast cancer treatment

Background and purpose: Human epidermal growth factor receptor 2 (HER2) is overexpressed in approximately 25% of breast cancer patients; therefore, its inhibition is a therapeutic target in cancer treatment. Experimental approach: In this study, two new variants of designed ankyrin repeat proteins (...

Full description

Bibliographic Details
Main Authors: Maryam Beheshti Isfahani, Karim Mahnam, Hooria Seyedhosseini-Ghaheh, Hamid Mir Mohammad Sadeghi, Hossein Khanahmad, Vajihe Akbari, Jaleh Varshosaz
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2023-01-01
Series:Research in Pharmaceutical Sciences
Subjects:
breast cancer; designed ankyrin repeat proteins; docking; molecular dynamic simulation.
Online Access:http://www.rpsjournal.net/article.asp?issn=1735-5362;year=2023;volume=18;issue=6;spage=626;epage=637;aulast=Isfahani

Internet

http://www.rpsjournal.net/article.asp?issn=1735-5362;year=2023;volume=18;issue=6;spage=626;epage=637;aulast=Isfahani

Similar Items